Cargando…
Accrual, Publication Bias, and the Coronavirus in 2020
The era of COVID19 reflects the importance, perhaps now more than ever, of transparency in the outcomes of trials small and large. The Oncologist Clinical Trial Results (CTR) section has endeavored to provide a remedy for the persistent problem of underreporting in clinical trials in oncology and th...
Autor principal: | Bates, Susan E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356711/ https://www.ncbi.nlm.nih.gov/pubmed/32462787 http://dx.doi.org/10.1634/theoncologist.2020-0455 |
Ejemplares similares
-
Participation in Cancer Clinical Trials: Researching the Causes of Low Accrual
por: Hallquist Viale, Pamela
Publicado: (2016) -
Accrual monitoring in cardiovascular trials
por: Baldi, Ileana, et al.
Publicado: (2017) -
Low-Overhead Accrual Failure Detector
por: Ren, Xiao, et al.
Publicado: (2012) -
Clinical Trial Accrual: Obstacles and Opportunities
por: Rimel, B. J.
Publicado: (2016) -
Publication bias and the chase for statistical significance
por: Marín-Franch, Iván
Publicado: (2018)